IGM Biosciences, Inc. Operating Lease Cost
IGM Biosciences, Inc. reported Operating Lease Cost of $7.92 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-03-06
- IGM Biosciences, Inc. operating lease, cost for the quarter ending 2021-12-31 was $1.20M, a 56.77% increase year-over-year.
- IGM Biosciences, Inc. operating lease, cost for the quarter ending 2021-09-30 was $1.19M, a 55.28% increase year-over-year.
- IGM Biosciences, Inc. operating lease, cost for the quarter ending 2021-06-30 was $955.00K, a 24.51% increase year-over-year.
- IGM Biosciences, Inc. operating lease, cost for the quarter ending 2021-03-31 was $786.00K, a 2.48% increase year-over-year.
- IGM Biosciences, Inc. operating lease, cost for fiscal 2024 was $7.92M, a 3.95% decline from fiscal 2023.
- IGM Biosciences, Inc. operating lease, cost for fiscal 2023 was $8.25M, a 32.70% increase from fiscal 2022.
- IGM Biosciences, Inc. operating lease, cost for fiscal 2022 was $6.22M, a 50.28% increase from fiscal 2021.
- IGM Biosciences, Inc. operating lease, cost for fiscal 2021 was $4.14M, a 34.80% increase from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $7.92M 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $8.25M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $6.22M 10-K · filed 2025-03-06 | |||
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $2.40M derived: sum of 2 quarters · filed 2024-03-07 | $3.35M derived: sum of 3 quarters · filed 2024-03-07 | $4.14M 10-K · filed 2024-03-07 |
| 2021-09-30 | $1.19M 10-Q · filed 2021-11-04 | $2.15M derived: sum of 2 quarters · filed 2021-11-04 | $2.93M 10-Q · filed 2021-11-04 | $3.70M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $955.00K 10-Q · filed 2021-08-09 | $1.74M 10-Q · filed 2021-08-09 | $2.51M derived: sum of 3 quarters · filed 2023-03-30 | $3.28M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $786.00K 10-Q · filed 2021-05-06 | $1.55M derived: sum of 2 quarters · filed 2023-03-30 | $2.32M derived: sum of 3 quarters · filed 2023-03-30 | $3.09M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $768.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.53M derived: sum of 2 quarters · filed 2023-03-30 | $2.30M derived: sum of 3 quarters · filed 2023-03-30 | $3.07M 10-K · filed 2023-03-30 |
| 2020-09-30 | $767.00K 10-Q · filed 2021-11-04 | $1.53M derived: sum of 2 quarters · filed 2021-11-04 | $2.30M 10-Q · filed 2021-11-04 | $2.33M derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-06-30 | $767.00K 10-Q · filed 2021-08-09 | $1.53M 10-Q · filed 2021-08-09 | $1.56M derived: sum of 3 quarters · filed 2022-03-29 | $2.24M derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-03-31 | $767.00K 10-Q · filed 2021-05-06 | $795.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.47M derived: sum of 3 quarters · filed 2022-03-29 | $1.99M derived: sum of 4 quarters · filed 2022-03-29 |
| 2019-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $702.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.23M derived: sum of 3 quarters · filed 2022-03-29 | $1.40M 10-K · filed 2022-03-29 |
| 2019-09-30 | $674.00K 10-Q · filed 2020-11-05 | $1.20M derived: sum of 2 quarters · filed 2020-11-05 | $1.37M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $523.00K 10-Q · filed 2020-08-06 | $694.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $171.00K 10-Q · filed 2020-05-07 |